-
HuiLiao Biomedical Raises RMB 100 Million in Pre-Series A Round for mRNA Development
•
China-based nucleic acid drug specialist Suzhou HuiLiao Biomedical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 14.35 million) in a pre-Series A financing round. The round was led by MING Bioventures, with participation from Shunwei Capital, China-Singapore Suzhou Industrial Park Private Equity Management Co., Ltd, and existing…
